TiffiniSmithVossMD
Neurology • Charlottesville, VAMovement Disorder, Neurodegenerative
VP, Clinical Development at PassageBio
Dr. Voss is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Lee St
Ground floor
Charlottesville, VA 22908Phone+1 434-924-5542Fax+1 434-982-1064
Education & Training
University of Pennsylvania Health SystemResidency, Neurology, 2004 - 2007- University of Pennsylvania Health SystemInternship, Internal Medicine, 2003 - 2004
Perelman School of Medicine at the University of PennsylvaniaClass of 2003
Certifications & Licensure
VA State Medical License 2009 - 2026- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Safety and Efficacy of Rasagiline in Restless Legs Syndrome Start of enrollment: 2010 Sep 01
Publications & Presentations
PubMed
- 164 citationsA phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine:Tiffini Voss, Richard B. Lipton, David W. Dodick, Nicole Dupre, Joy Yang Ge
Cephalalgia. 2016-06-06 - 39 citationsRandomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease.Tiffini Voss, Jerry Li, Jeffrey L Cummings, Martin R. Farlow, Christopher Assaid
Alzheimer's & Dementia. 2018-01-01 - 240 citationsA Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease: No Evidence of BenefitM. Flint Beal, David Oakes, Ira Shoulson, Claire Henchcliffe, Wendy R. Galpern
JAMA Neurology. 2014-05-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
